Yan Dan, Weisshaar Marco, Lamb Kristen, Chung Hokyung K, Lin Michael Z, Plemper Richard K
Institute for Biomedical Sciences, Georgia State University , Atlanta, Georgia 30303-3222, United States.
Department of Biology, Stanford University , Stanford, California 94305-5020, United States.
Biochemistry. 2015 Sep 15;54(36):5589-604. doi: 10.1021/acs.biochem.5b00623. Epub 2015 Sep 1.
Myxoviruses such as influenza A virus (IAV) and respiratory syncytial virus (RSV) are major human pathogens, mandating the development of novel therapeutics. To establish a high-throughput screening protocol for the simultaneous identification of pathogen- and host-targeted hit candidates against either pathogen or both, we have attempted co-infection of cells with IAV and RSV. However, viral replication kinetics were incompatible, RSV signal window was low, and an IAV-driven minireplicon reporter assay used in initial screens narrowed the host cell range and restricted the assay to single-cycle infections. To overcome these limitations, we developed an RSV strain carrying firefly luciferase fused to an innovative universal small-molecule assisted shut-off domain, which boosted assay signal window, and a hyperactive fusion protein that synchronized IAV and RSV reporter expression kinetics and suppressed the identification of RSV entry inhibitors sensitive to a recently reported RSV pan-resistance mechanism. Combined with a replication-competent recombinant IAV strain harboring nanoluciferase, the assay performed well on a human respiratory cell line and supports multicycle infections. Miniaturized to 384-well format, the protocol was validated through screening of a set of the National Institutes of Health Clinical Collection (NCC) in quadruplicate. These test screens demonstrated favorable assay parameters and reproducibility. Application to a LOPAC library of bioactive compounds in a proof-of-concept campaign detected licensed antimyxovirus therapeutics, ribavirin and the neuraminidase inhibitor zanamivir, and identified two unexpected RSV-specific hit candidates, Fenretinide and the opioid receptor antagonist BNTX-7. Hits were evaluated in direct and orthogonal dose-response counterscreens using a standard recRSV reporter strain expressing Renilla luciferase.
甲型流感病毒(IAV)和呼吸道合胞病毒(RSV)等黏液病毒是主要的人类病原体,因此需要开发新型治疗方法。为建立一种高通量筛选方案,以同时鉴定针对病原体或两者的病原体靶向和宿主靶向的命中候选物,我们尝试用IAV和RSV共同感染细胞。然而,病毒复制动力学不兼容,RSV信号窗口较低,并且初始筛选中使用的IAV驱动的微型复制子报告基因检测缩小了宿主细胞范围,并将检测限制在单周期感染。为克服这些限制,我们开发了一种携带与创新的通用小分子辅助关闭结构域融合的萤火虫荧光素酶的RSV毒株,该毒株提高了检测信号窗口,以及一种超活性融合蛋白,该蛋白使IAV和RSV报告基因表达动力学同步,并抑制了对最近报道的RSV泛耐药机制敏感的RSV进入抑制剂的鉴定。结合携带纳米荧光素酶的具有复制能力的重组IAV毒株,该检测在人呼吸道细胞系上表现良好,并支持多周期感染。该方案小型化为384孔板形式,通过对一组美国国立卫生研究院临床收藏(NCC)进行一式四份筛选进行了验证。这些测试筛选显示了良好的检测参数和可重复性。在概念验证活动中应用于生物活性化合物LOPAC文库,检测到已获许可的抗黏液病毒治疗药物利巴韦林和神经氨酸酶抑制剂扎那米韦,并鉴定出两种意想不到的RSV特异性命中候选物,芬维A胺和阿片受体拮抗剂BNTX-7。使用表达海肾荧光素酶的标准recRSV报告毒株,在直接和正交剂量反应反筛选中对命中物进行了评估。